NDAINTRAVENOUSPOWDER
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DAPTOMYCIN (daptomycin) by MAIA Biotechnology is [see clinical pharmacology ()]. Approved for bacteremia, soft tissue infections, infective endocarditis and 9 more indications. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibiotic administered intravenously as a powder for injection. It treats serious gram-positive bacterial infections including bacteremia, endocarditis, osteomyelitis, and skin/soft tissue infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug works by disrupting bacterial cell membrane integrity, leading to rapid bactericidal activity.
Growth
Recent 2024 approval positions this as an emerging growth product with expanding market opportunity and expanding team headcount for commercial and medical functions.
Mechanism of Action
[see Clinical Pharmacology ()].
Pharmacologic Class:
Lipopeptide Antibacterial
Indications (12)
Worked on DAPTOMYCIN at MAIA Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.